Las Vegas—Oral tacrolimus might deserve consideration as a first-line therapy in severe esophageal lichen planus, according to response rates in a retrospective study at a center where this treatment has been offered to many patients.
“Using tacrolimus at doses 50% to 75% lower than those [typically used] in transplant patients reduced the inflammatory and fibrostenotic components of [esophageal lichen planus] and was safe,” reported Keshav Kukreja, MD, a fellow in the Division